Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial
Open Forum Infectious Diseases · 02.06.2026 · 13 (6)
DOI: 10.1093/ofid/ofag142 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 22.06.2026. Verfasst von Sean W X Ong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research, Health Research Council of New Zealand, Australian National Medical Research Council.
Abstract (Originalsprache)
Background
Desirability of Outcome Ranking (DOOR) with Response Adjusted for Duration of Antibiotic Risk (RADAR) has been suggested as an outcome for antibiotic duration trials. An endpoint incorporating a measure of antimicrobial resistance may better reflect trade-offs between different antibiotic strategies.
Methods
We constructed a novel endpoint, DOOR-FRAME (Framework for Resistance Assessment and Microbiologic Evaluation), and applied it as a proof-of-concept in a post hoc analysis of the BALANCE trial comparing 7- versus 14-day antibiotic duration for uncomplicated non-Staphylococcus aureus bloodstream infection (BSI). The DOOR comprised mortality, readmission, and reinfection, while the FRAME component was a quantitative composite measure of incident Clostridioides difficile infection (CDI) and positive cultures for antibiotic-resistant organisms (AROs). We included BALANCE patients in Ontario who consented to data linkage to provincial health administrative databases. We calculated the probabilistic index (PI), the probability of a randomly selected patient in the 7-day group having a better outcome at 180 days.
Results
Two hundred seventy-one participants were included. The DOOR distributions were similar between the 7- and 14-day groups, with PI of 46.8% (95% CI 40.4%–53.2%) using DOOR alone. Nine (6.9%) and 12 (8.5%) patients in the 7 and 14-day group respectively had ARO/CDI within 180 days. Probabilistic index was 53.6% (95% CI 46.7%–60.4%) with DOOR-RADAR and 47.4% (95% CI 40.9%–53.8%) with DOOR-FRAME.
Conclusions
There were no significant differences in DOOR outcomes at 180 days between patients with uncomplicated BSI treated with 7 versus 14-day antibiotic duration. Incorporating a novel measure of antimicrobial resistance did not change interpretation of the trial.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Victorian Infectious Diseases Service, Royal Melbourne Hospital, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
- ICES, Toronto, Ontario, Canada.
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Sean W X Ong, Ruxandra Pinto, Steven Y C Tong
Förderung
- Canadian Institutes of Health Research
- Health Research Council of New Zealand
- Australian National Medical Research Council
- Physicians Services Incorporated Ontario
- Ontario Ministry of Health and Long-term Care Innovation Fund
- Accelerating Clinical Trials
- Consortium and Health Data Research Network
- Canada Clinical Trials Working Group
Zitieren
APA
Ong, S. W. X., Patrikar, A., Pinto, R., Mahar, R. K., Rishu, A., Davis, J. S., Fowler, R. A., Tong, S. Y. C., & Daneman, N. (2026). Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial. Open Forum Infectious Diseases, 13(6). https://doi.org/10.1093/ofid/ofag142
Vancouver
Ong SWX, Patrikar A, Pinto R, Mahar RK, Rishu A, Davis JS, et al. Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial. Open Forum Infectious Diseases. 2026;13(6). doi:10.1093/ofid/ofag142
BibTeX
@article{Ong2026,
author = {Ong, Sean W X and Patrikar, Aditi and Pinto, Ruxandra and Mahar, Robert K and Rishu, Asgar and Davis, Joshua S and Fowler, Robert A and Tong, Steven Y C and Daneman, Nick},
title = {Application of a Novel Desirability of Outcome Ranking Endpoint Incorporating a Framework for Resistance Assessment and Microbiologic Evaluation in Antibiotic Trials: A Proof-of-Concept in a Post Hoc Analysis of the BALANCE Trial},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {6},
doi = {10.1093/ofid/ofag142}
}
EUVIMED